Clinical Trial Update: CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT [Phase 3]

View source ↗

Summary

A Phase 3 trial update suggests that a CMV-specific T cell immunity test could indicate prophylaxis with letermovir after allogeneic hematopoietic stem cell tra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy

Drugs mentioned

• Letermovir (letermovir)

Snippet

Sponsor: Ruijin Hospital | Conditions: Hematologic Malignancy | Phase 3 | Status: ACTIVE_NOT_RECRUITING